Research on hormone therapy and its effects. Covers menopause symptom relief, bronchiectasis risk, dementia links, and Alzheimer's risk.
A follow-up study of women who stopped taking hormone therapy after a clinical trial found an increased risk of cancer, with higher rates of invasive breast cancer and other cancers. Cardiovascular events were comparable between the two groups.
A follow-up study of WHI participants found an increased risk of invasive breast cancer and other cancers in women taking estrogen plus progestin. The risk of heart disease, stroke, and blood clots decreased after the intervention was stopped.
A follow-up study of the Women's Health Initiative confirms that long-term use of combination hormone therapy in healthy postmenopausal women increases risks of heart disease, stroke, and blood clots. After stopping hormone therapy, cardiovascular disease risk decreases but overall risks remain high.
A study of 3,987 older men found that those with low free testosterone levels had a higher prevalence of depression, with men in the lowest quintile having three times the odds of depression compared to those in the highest quintile. Researchers suggest that hormone imbalances may contribute to this link.
Researchers have found that hormone replacement therapy does not significantly affect the risk of developing or exacerbating rheumatoid arthritis. The study analyzed data from over 27,000 postmenopausal women taking part in a clinical trial, revealing no notable differences between those on hormone replacement therapy and placebo groups.
Researchers at Thomas Jefferson University have discovered that blocking the signaling protein Stat5 can effectively kill prostate cancer cells and inhibit tumor growth. This finding holds promise for treating advanced prostate cancer, particularly hormone-resistant cases.
Researchers have discovered that heart hormones can eliminate human pancreatic and breast cancers in mice, reducing tumors by up to 97%. The treatment has shown no side effects and has the potential to make cancer a chronic condition.
A recent study published in Archives of Internal Medicine found that combined hormone therapy significantly increases the risk of abnormal mammograms and breast biopsies, compromising their diagnostic performance. The research involved 16,608 post-menopausal women and revealed a four percent greater risk of mammogram abnormalities afte...
Researchers at Gladstone and UCSF found that growth hormone therapy stimulates the production of vital T-cells, leading to increased thymic mass and improved immune function. The study suggests that this treatment could help HIV-infected patients rebuild their compromised immune systems.
Researchers are developing new drugs that can modulate male hormone receptors to improve muscle weight without stimulating prostate glands. Studies have shed light on the complex mechanisms behind estrogen receptors in different tissues.
Men with localized prostate cancer who received male hormone suppression therapy and radiation treatment had longer survival rates. However, those with moderate to high levels of comorbid illnesses did not experience this effect. Combination therapy improved overall survival in men without severe comorbidity.
Postmenopausal women taking combined estrogen/progestin hormone-replacement therapy for three years or more face a significant increased risk of developing various forms of lobular breast cancer. The study, which confirms previous reports, suggests that even short exposure to such hormones may confer an increased risk.
Researchers discovered that Gas6 protein increases cell signaling in response to Epo treatment, enhancing its therapeutic potential for treating anemia. The study also found that mice deficient in Gas6 have decreased sensitivity to Epo and reduced ability to recover from anemia.
Researchers found that a short course of hormonal therapy before and with radiation therapy slowed cancer growth by up to eight years, particularly the development of bone metastases. This delayed cancer progression increased survival rates among older men with potentially aggressive prostate cancer.
Researchers at Thomas Jefferson University have found that nearly all recurrent prostate cancers resistant to hormone therapy activate a signaling protein called Stat5, making it a potential drug target. The convergence of two biological pathways may also contribute to the development of aggressive hormone-resistant tumors.
Researchers argue that female sex hormones play a critical role in mood disorders, and studies are needed to understand their effects. Hormonal fluctuations during times of menstruation or menopause may contribute to the increased vulnerability of women to poor mental health.
Researchers developed a mathematical model predicting optimal growth hormone dose for children with abnormal growth, showing improved predictive accuracy. The model uses data on birth weight, height before and during treatment, and blood hormone levels to determine individual response.
A recent study has found that progesterone has limited benefits for mice with Alzheimer's symptoms, but inhibits some of estrogen's beneficial effects when taken together. The study suggests that the constant daily dosage of progesterone may be antagonizing its potential benefits.
Prostate cancer patients undergoing hormone therapy who walked five times a week maintained or gained bone density, while those who didn't exercise lost more than two percent of their bone density. A nurse-directed home-based walking program improved physical function and managed symptoms during radiation and hormone treatment.
EpiVax receives $351,000 from JDRF to develop Epi-13, a novel therapeutic that reduces harmful immune responses and preserves insulin production. The approach uses natural regulatory T cells to induce antigen-specific adaptive tolerance induction.
A Swiss study suggests that surgery is the most effective treatment option for long-term prostate cancer survival, particularly among younger patients and those with poorly differentiated tumors. The study found higher 10-year survival rates for men who underwent prostatectomy compared to radiotherapy or watchful waiting.
A study published by the American Academy of Neurology found that hormone therapy taken in early post-menopause has no effect on women's memory, but may lead to increased sexual interest. The research involved 180 women who underwent tests on cognitive function, emotional status, and sleep.
A study led by Pauline Maki found that hormone therapy increased sexual interest and reduced hot flashes in younger mid-life women, but did not improve memory performance. The therapy combination of estrogen and progesterone showed a 32% increase in sexual thoughts and a 44% increase in sexual interest compared to the placebo group.
Researchers found that hair follicles on the head have the potential to become erythropoietin factories, potentially treating EPO-related anemia. This discovery opens doors to a new approach for treating severe anemia associated with kidney failure and chemotherapy.
Only 29% of women surveyed knew about the landmark hormone therapy study two years after its announcement, highlighting a flawed mechanism for communicating crucial health information to patients. The study found that discussions with physicians were key to retaining this knowledge, but many women reported never having such conversations.
Scientists at the University of Sheffield have developed a long-acting growth hormone that can promote growth over ten days with just one injection. This technology could reduce the need for frequent injections in children and adults with growth hormone disorders.
A pilot study by Mayo Clinic researchers found that flaxseed therapy decreased hot flashes in postmenopausal women by 50% and improved their quality of life. The study also showed improvements in mood, joint pain, and overall health.
The study found that women who had both ovaries removed but were treated with estrogen until age 50 did not have an increased risk of cognitive impairment or dementia. Women who had one or both ovaries removed before menopause faced a higher long-term risk of cognitive impairment or dementia compared to those who retained their ovaries.
A recent decline in breast cancer incidence is attributed to a drop in postmenopausal hormone therapy use. This finding contradicts the assumption that decreased mammography screening is responsible for the decline.
Scientists at Georgetown University Medical Center have discovered a new gene, XBP1, that contributes to Tamoxifen resistance in breast cancer cells. This finding may enable oncologists to screen women for responsiveness to these treatments and provide a clue for reversing resistance.
Researchers at Thomas Jefferson University found that colon cancer is caused by a lack of hormones that regulate intestinal epithelial cells. Hormone replacement therapy may prevent or treat the disease, shifting the focus from genetic to endocrine aspects.
A recent study found a significant decline in breast cancer incidence in 2003, coinciding with a drop in hormone therapy use. Breast density and sex hormone levels are also independent risk factors for breast cancer in postmenopausal women.
A new study published in CANCER journal found that group therapy does not prolong the lives of women with metastatic breast cancer. However, women with estrogen receptor-negative tumors showed a survival benefit from group therapy.
A meta-analysis of 29 studies found that incretin-based therapy improves glycemia, particularly postprandial glycemia, and has a favorable or neutral effect on weight. However, glucagon-like peptide 1 analogues are associated with gastrointestinal adverse effects, while DPP4 inhibitors have an increased risk of infection.
A pilot study found that gonadotropin-releasing hormone antagonists can suppress ovarian function in women receiving chemotherapy, protecting their fertility. The treatment was well-tolerated with minimal side effects and restored ovarian function after chemotherapy stopped.
A new algorithm for personalized ovarian stimulation therapy has been developed, demonstrating improved pregnancy rates in women undergoing fertility treatment. The formula, based on four easily measured patient characteristics, was tested in a prospective clinical study involving 161 patients.
A new study conducted at Mount Sinai School of Medicine found that cyclical estrogen injections protected brain cells from age-related deterioration. The research suggests that a critical window of opportunity exists in which estrogen therapy may be helpful in preventing memory loss, and that timing is crucial.
A substudy of the Women's Health Initiative found that younger postmenopausal women on estrogen-alone hormone therapy had 30-40% less coronary artery calcium than those without hormone therapy. However, the benefits of estrogen for preventing cardiovascular disease are uncertain and should not be used as a preventive measure.
The recent WHI-CACS study confirms estrogen therapy is cardioprotective, reducing atherosclerosis and coronary events. Early initiation of hormone therapy may even reduce the risk of coronary artery disease.
A follow-up study shows that estrogen use is associated with lower levels of calcified plaque in coronary arteries, a potential indicator of heart disease. However, other health risks, such as increased risk of blood clots and stroke, must still be considered before starting estrogen therapy.
New data from the Women's Health Initiative study show that women aged 50-59 taking oral estrogen therapy have significantly less coronary artery calcification compared to those taking placebo. This finding supports the initiation of estrogen therapy in these younger menopausal women to reduce bone loss and alleviate symptoms.
Researchers at the University of Edinburgh have shown that hormone therapy can prolong the life of some ovarian cancer patients by up to three years. The study found that targeted use of an anti-oestrogen drug could slow the growth and spread of disease in highly sensitive cancers.
Researchers at Mayo Clinic have discovered that low doses of gabapentin substantially reduce hot flashes in patients undergoing anti-hormonal treatment for prostate cancer. The study found that gabapentin reduced the frequency and intensity of hot flashes by up to 46% in men receiving androgen deprivation therapy.
A recent survey found that three-quarters of women with breast cancer were not informed about their risk of recurrence, despite 96% relying on their healthcare provider for information. The study highlights the need for better communication between healthcare professionals and patients to ensure they receive life-saving information.
Researchers found that COX inhibitors like traditional nonsteroidal anti-inflammatory drugs (NSAIDs) may counteract the potential heart-protective effects of estrogen therapy. Women who used NSAIDs with hormone replacement therapy had a lost protective effect against heart attack and stroke.
Researchers are investigating the best time to start hormone therapy, its impact on cognition and mood, and the most beneficial form of estrogen. The $3.4 million KEEPS study aims to clarify the safety and effectiveness of hormone therapy in perimenopausal women.
Researchers found that traditional nonsteroidal anti-inflammatory drugs (NSAIDs) may counteract the heart-protective effect of hormone replacement therapy in women. Current use of hormone replacement therapy was associated with a significantly lower risk of heart attack than non-use, but NSAID use negated this benefit.
A meta-analysis of 16 trials found LHRH agonists effective in reducing breast cancer recurrence by nearly 13% and death after recurrence by 15%. The treatment was only beneficial for premenopausal women with hormone-sensitive breast cancer under 40.
The International Menopause Society has updated its recommendations on hormone therapy for postmenopausal women, highlighting the importance of individualized treatment and a balanced approach. The new guidelines take into account the latest scientific evidence and aim to provide a global framework for menopause management.
Researchers found that a lifestyle change intervention significantly decreased weight, cholesterol, and LDL-C in women who discontinued hormone replacement therapy. This non-pharmacological approach is safe and effective for reducing CVD risk factors in postmenopausal women.
A small pilot study suggests that testosterone treatment is safe and well-tolerated and may reduce symptoms, slow brain degeneration, and increase muscle mass in men with relapsing-remitting multiple sclerosis. Testosterone treatment showed a possible neuroprotective effect on the brain.
The AGA Institute's Obesity Task Force Report highlights the need for a comprehensive approach to addressing obesity, considering its impact on healthcare budgets and societal practices. The report emphasizes the role of gastroenterology in treating obesity, with novel therapies and policies being developed.
A pilot study at UCLA found that testosterone gel reduced MS symptoms, slowed brain degeneration, and increased muscle mass in men with relapsing-remitting multiple sclerosis. The study suggests a possible neuroprotective effect of testosterone treatment in men with MS.
Researchers at the University of North Carolina Health Care identified protein Ack1 as a trigger for advanced prostate cancer recurrence in men undergoing hormone treatment. This finding may lead to the development of targeted therapies against this protein.
Research presented at the American Academy of Neurology's meeting found that women using estrogen hormone therapy before age 65 had a nearly 50% lower risk of developing Alzheimer's disease or dementia. The study followed over 7,000 healthy women aged 65-79 for an average of five years.
A randomized clinical trial found that topical testosterone cream did not improve libido in postmenopausal female cancer survivors compared to a placebo. The study suggests that estrogen levels may be a crucial factor in the effectiveness of testosterone therapy for sexual desire in women.
A sharp decline in breast-cancer incidence in 2003, followed by relative stabilization, is attributed to the drop in hormone-replacement therapy among postmenopausal women. Researchers estimate a 44,000 fewer breast cancers over two years, with the reduction most evident in estrogen-receptor-positive tumors.
Researchers found a strong association between HRT use and decreased breast cancer incidence, with a 6.7% decline between 2002 and 2003. The lowest rate seen since about 1987 was maintained in 2004, primarily in estrogen-receptor-positive cancers.
A sharp decline in breast cancer cases in 2003 may be linked to a decrease in hormone replacement therapy (HRT) use, with prescriptions dropping by 60% between 2001 and 2004. HRT use was associated with an increased risk of breast cancer, particularly among postmenopausal women.
Researchers found females outperform males in using landmarks for navigation, even with blocked testosterone levels. This study provides insight into brain development and may lead to better treatments for disorders like ADHD and Alzheimer's.